Statistics from Altmetric.com
- biological therapy
- antirheumatic agents
- autoimmune diseases
- tumor necrosis factor inhibitors
- immune system diseases
We read with great interest the European League against Rheumatism (EULAR) provisional guidelines regarding rheumatic and musculoskeletal disease management during the COVID-19 pandemic recently published by Landewé et al.1 While the COVID-19 pandemic continues across the world, rheumatology care has been enormously impacted. In the strive to adapt, telemedicine and telehealth have taken a predominant role in our everyday practice. Additionally, our treatment schemes have changed and sometimes have been deferred. Initial questions from rheumatologists—such as ‘are my patients with rheumatic diseases at higher risk of COVID-19?’ and ‘should I stop their anti-rheumatic treatment (biologic or not) during the COVID-19 pandemic?’—slowly get answered as evidence continues to accumulate.
However, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is here …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.